$ACT Recent Headlines DEA restricts narcotic p
Post# of 44845
Posted On: 09/09/2014 11:33:22 AM
$ACT Recent Headlines
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
Mylan to start selling generic Celebrex in May 7:23 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - Russ Britt
Staples awash in red; eBay up as Icahn posts new letter 5:09 p.m. March 6, 2014 - Sue Chang
Icahn Enterprises reports profit up 144% in 2013 11:23 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 12:12 p.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 5:46 p.m. Feb. 24, 2014 - Victor Reklaitis
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Synergy Pharmaceuticals Could Be A Diamond In The Rough 12:30 p.m. Sept. 8, 2014 - Seeking Alpha
Pfizer: You Won't Fool Me Twice 1:28 a.m. Sept. 7, 2014 - Seeking Alpha
IBD 50 Showing Little Distress, But Few Big Winners 5:45 p.m. Sept. 5, 2014 - Investors Business Daily
Orexigen Gets Weight Loss Drug Patent, May See Runup Into Approval Decision 11:46 a.m. Sept. 5, 2014 - Seeking Alpha
The Top Net Buys Of The Hedge Fund Gurus 5:59 p.m. Sept. 4, 2014 - GuruFocus.com
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog 4:30 p.m. Sept. 4, 2014 - Zacks.com
3 Stocks Advancing The Health Care Sector 1:03 p.m. Sept. 4, 2014 - TheStreet.com
Sterne Agee Raises Actavis plc Estimates, Price Target 10:58 a.m. Sept. 4, 2014 - benzinga.com
Shares Of Actavis Are Up ~1.5% On FDA Approval 9:55 a.m. Sept. 4, 2014 - benzinga.com
UPDATE: Morgan Stanley Reiterates On Actavis plc As M&A Could Offer Additional Upside 9:00 a.m. Sept. 4, 2014 - benzinga.com
Actavis's Watson Labs ANDA Approved By FDA 8:41 a.m. Sept. 4, 2014 - benzinga.com
New Lifetime High For Actavis (ACT) 9:46 a.m. Sept. 3, 2014 - TheStreet.com
FDA accepts eluxadoline NDA 2:02 p.m. Sept. 2, 2014 - Seeking Alpha
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog 4:40 p.m. Aug. 28, 2014 - Zacks.com
Top 4 BlackRock Funds to Buy Now 6:34 a.m. Aug. 28, 2014 - InvestorPlace.com
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2014 Update 10:34 a.m. Aug. 23, 2014 - Seeking Alpha
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog 4:55 p.m. Aug. 22, 2014 - Zacks.com
Clampdown on Popular Painkillers 12:18 p.m. Aug. 22, 2014 - The Wall Street Journal Interactive Edition
Wall Street Breakfast: Restrictions Imposed On Citigroup's Hedge Fund Sales 6:33 a.m. Aug. 22, 2014 - Seeking Alpha
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Today - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD 4:30 p.m. July 21, 2014 - PR Newswire - PRF
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira 5:10 a.m. July 14, 2014 - PR Newswire - PRF
Actavis Confirms Generic Diclegis® Patent Challenge 4:25 p.m. July 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Ampyra® Patent Challenge 4:05 p.m. July 8, 2014 - PR Newswire - PRF
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma 5:30 a.m. July 4, 2014 - PR Newswire - PRF
Impax Acquires Two Products from Actavis 4:05 p.m. July 2, 2014 - PR Newswire - PRF
Actavis Completes Acquisition of Furiex Pharmaceuticals 8:46 a.m. July 2, 2014 - PR Newswire - PRF
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition 8:00 a.m. July 2, 2014 - PR Newswire - PRF
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger 3:15 p.m. July 1, 2014 - BusinessWire - BZX
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
Mylan to start selling generic Celebrex in May 7:23 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - Russ Britt
Staples awash in red; eBay up as Icahn posts new letter 5:09 p.m. March 6, 2014 - Sue Chang
Icahn Enterprises reports profit up 144% in 2013 11:23 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 12:12 p.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 5:46 p.m. Feb. 24, 2014 - Victor Reklaitis
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Synergy Pharmaceuticals Could Be A Diamond In The Rough 12:30 p.m. Sept. 8, 2014 - Seeking Alpha
Pfizer: You Won't Fool Me Twice 1:28 a.m. Sept. 7, 2014 - Seeking Alpha
IBD 50 Showing Little Distress, But Few Big Winners 5:45 p.m. Sept. 5, 2014 - Investors Business Daily
Orexigen Gets Weight Loss Drug Patent, May See Runup Into Approval Decision 11:46 a.m. Sept. 5, 2014 - Seeking Alpha
The Top Net Buys Of The Hedge Fund Gurus 5:59 p.m. Sept. 4, 2014 - GuruFocus.com
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog 4:30 p.m. Sept. 4, 2014 - Zacks.com
3 Stocks Advancing The Health Care Sector 1:03 p.m. Sept. 4, 2014 - TheStreet.com
Sterne Agee Raises Actavis plc Estimates, Price Target 10:58 a.m. Sept. 4, 2014 - benzinga.com
Shares Of Actavis Are Up ~1.5% On FDA Approval 9:55 a.m. Sept. 4, 2014 - benzinga.com
UPDATE: Morgan Stanley Reiterates On Actavis plc As M&A Could Offer Additional Upside 9:00 a.m. Sept. 4, 2014 - benzinga.com
Actavis's Watson Labs ANDA Approved By FDA 8:41 a.m. Sept. 4, 2014 - benzinga.com
New Lifetime High For Actavis (ACT) 9:46 a.m. Sept. 3, 2014 - TheStreet.com
FDA accepts eluxadoline NDA 2:02 p.m. Sept. 2, 2014 - Seeking Alpha
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog 4:40 p.m. Aug. 28, 2014 - Zacks.com
Top 4 BlackRock Funds to Buy Now 6:34 a.m. Aug. 28, 2014 - InvestorPlace.com
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2014 Update 10:34 a.m. Aug. 23, 2014 - Seeking Alpha
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog 4:55 p.m. Aug. 22, 2014 - Zacks.com
Clampdown on Popular Painkillers 12:18 p.m. Aug. 22, 2014 - The Wall Street Journal Interactive Edition
Wall Street Breakfast: Restrictions Imposed On Citigroup's Hedge Fund Sales 6:33 a.m. Aug. 22, 2014 - Seeking Alpha
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Today - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD 4:30 p.m. July 21, 2014 - PR Newswire - PRF
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira 5:10 a.m. July 14, 2014 - PR Newswire - PRF
Actavis Confirms Generic Diclegis® Patent Challenge 4:25 p.m. July 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Ampyra® Patent Challenge 4:05 p.m. July 8, 2014 - PR Newswire - PRF
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma 5:30 a.m. July 4, 2014 - PR Newswire - PRF
Impax Acquires Two Products from Actavis 4:05 p.m. July 2, 2014 - PR Newswire - PRF
Actavis Completes Acquisition of Furiex Pharmaceuticals 8:46 a.m. July 2, 2014 - PR Newswire - PRF
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition 8:00 a.m. July 2, 2014 - PR Newswire - PRF
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger 3:15 p.m. July 1, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼